|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2001, Vol. 98, No. 3, pp. 594-596
GENE THERAPY
Lentivirus administration to rat muscle provides efficient
sustained expression of erythropoietin
Jurgen Seppen,
Simon C. Barry,
Brandon Harder, and
William R. A. Osborne
From the Department of Pediatrics, University of
Washington School of Medicine, Seattle, WA.
A lentivirus pseudotyped with vesicular stomatitis virus G
protein (VSV-G) encoding rat erythropoietin (EPO) complementary DNA was
administered to rat skeletal muscle and red blood cell production was
serially monitored. After a single intramuscular injection hematocrit
values increased and reached a plateau at about 35 days and were
sustained for at least 14 months. Virus doses of 6 × 107
infectious units and 6 × 106 infectious units produced
significantly increased mean hematocrit values of 68.5% ± 2.1%
(P < .001, n = 4) and 52.7% ± 1.3%
(P < .001, n = 3), respectively, over values of
control animals receiving normal saline (46.2% ± 1.5%, n = 2). A
polymerase chain reaction (PCR) assay for vector sequences in genomic
DNA showed muscle tissue at the site of injection was positive and
undetectable in liver, spleen, kidney, and lung. The intramuscular
administration of lentivirus provided a dose-responsive, highly
efficient and sustained EPO gene delivery, suggesting these
vectors may be applied generally to the systemic delivery of proteins
such as hormones and clotting factors.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Yanay, S. C. Barry, L. J. Katen, M. Brzezinski, L. Y. Flint, J. Christensen, D. Liggitt, D. C. Dale, and W. R. A. Osborne
Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery
Blood,
September 15, 2003;
102(6):
2046 - 2052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Binley, Z. Askham, S. Iqball, H. Spearman, L. Martin, M. de Alwis, A. J. Thrasher, R. R. Ali, P. H. Maxwell, S. Kingsman, et al.
Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy
Blood,
September 18, 2002;
100(7):
2406 - 2413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Martin-Touaux, J.P. Puech, D. Chateau, C. Emiliani, E.J. Kremer, N. Raben, B. Tancini, A. Orlacchio, A. Kahn, and L. Poenaru
Muscle as a putative producer of acid {alpha}-glucosidase for glycogenosis type II gene therapy
Hum. Mol. Genet.,
July 1, 2002;
11(14):
1637 - 1645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hannallah, B. Peterson, J. R. Lieberman, F. H. Fu, and J. Huard
Gene Therapy in Orthopaedic Surgery
J. Bone Joint Surg. Am.,
June 1, 2002;
84(6):
1046 - 1061.
[Full Text]
|
|
|
| |
